Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.

OBJECTIVES: To perform a literature review and develop recommendations for the use of rituximab in ANCA-associated vasculitis. METHODS: A committee of experts (five rheumatologists, five nephrologists and one paediatrician) conducted a modified Delphi exercise to identify five topics for a systemat...

Bibliografske podrobnosti
Main Authors:	Guerry, M, Brogan, P, Bruce, I, D'Cruz, D, Harper, L, Luqmani, R, Pusey, C, Salama, A, Scott, D, Savage, C, Watts, R, Jayne, DR
Format:	Journal article
Jezik:	English
Izdano:	2012

Podobne knjige/članki

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
od: Flossmann, O, et al.
Izdano: (2006)

Anti-neutrophil cytoplasmic antibody associated vasculitis following rituximab: Outcomes of 50 patients in a tertiary single centre
od: Fahidah Alenzi, et al.
Izdano: (2023-09-01)

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
od: Latimer, N, et al.
Izdano: (2014)

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
od: Latimer, N, et al.
Izdano: (2014)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
od: Hellmich, B, et al.
Izdano: (2007)

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.
od: Basu, N, et al.
Izdano: (2014)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
od: Alan D. Salama
Izdano: (2020-01-01)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
od: Mukhtyar, C, et al.
Izdano: (2006)

The UK & Ireland Vasculitis Registry (UKIVAS): Cross-sectional data on the first 2290 Patients with anti-neutrophil cytoplasm (ANCA) associated vasculitis (AAV)
od: Luqmani, R, et al.
Izdano: (2017)

Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis
od: Pearce, F, et al.
Izdano: (2017)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
od: Mukhtyar, C, et al.
Izdano: (2008)

Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
od: Michael A Paley, et al.
Izdano: (2019-01-01)

The United Kingdom and Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis
od: Luqmani, R, et al.
Izdano: (2017)

Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
od: Robson, J, et al.
Izdano: (2017)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
od: Merkel, P, et al.
Izdano: (2009)

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
od: de Groot, K, et al.
Izdano: (2009)

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.
od: Robson, J, et al.
Izdano: (2014)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
od: Jones, R, et al.
Izdano: (2010)

Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
od: Feldmann, M, et al.
Izdano: (2006)

Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
od: Saket Jha, et al.
Izdano: (2019-01-01)

Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis
od: Enrique Morales, et al.
Izdano: (2025-01-01)

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians
od: David Massicotte-Azarniouch, et al.
Izdano: (2024-08-01)

Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis
od: Thomas Hellmark, et al.
Izdano: (2019-03-01)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
od: Jones, R, et al.
Izdano: (2009)

A disease-specific patient-reported outcome for anti-neutrophil cytoplasmic antibody–associated vasculitis: scale structure and measurement properties of the anti-neutrophil cytoplasmic antibody-associated vasculitis patient-reported outcome measure
od: Robson, J, et al.
Izdano: (2017)

Use of a computerised system to facilitate evaluation of anti-neutrophil cytoplasm (ANCA Associated) vasculitis (AAV) and other forms of systemic vasculitis
od: Luqmani, R, et al.
Izdano: (2017)

The role of neutrophils in vasculitis associated with antineutrophil cytoplasmic antibodies
od: E. N. Vorkel, et al.
Izdano: (2024-12-01)

Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
od: Zhi-Ying Li, et al.
Izdano: (2020-08-01)

Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
od: Moog P, et al.
Izdano: (2015-11-01)

Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report
od: Xinyu Weng, et al.
Izdano: (2022-03-01)

Eular recommendations for vasculitis
od: Luqmani, R, et al.
Izdano: (2007)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
od: Walsh, M, et al.
Izdano: (2011)

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis
od: Despina Michailidou, et al.
Izdano: (2022-06-01)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
od: Lapraik, C, et al.
Izdano: (2007)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
od: Ntatsaki, E, et al.
Izdano: (2014)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation
od: Valentina Binda, et al.
Izdano: (2021-12-01)

Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
od: Cheng-Hua Weng, et al.
Izdano: (2019-12-01)

Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis
od: Naidan Zhang, MS, et al.
Izdano: (2022-06-01)

Long- term outcome of paediatric patients with ANCA vasculitis
od: Pusey Charles D, et al.
Izdano: (2011-06-01)

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
od: Laura S. van Dam, et al.
Izdano: (2020-12-01)